Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0R3IK
|
||||
Former ID |
DIB009351
|
||||
Drug Name |
EPI-0030
|
||||
Synonyms |
APX-003; SIM-BD-0801; Humanized anti-VEGF mAbs (RabMab/MLG, cancer), Apexigen/Simcere; Humanized anti-VEGF mAbs (RabMab/MLG, cancer), Epitomics/Simcere
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Investigative | [543499] | ||
Company |
Epitomics Inc
|
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Modulator | [543499] | |
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY network | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.